{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-303051","form_type":"8-K","ticker":"LENZ","cik":"0001815776","company_name":"LENZ Therapeutics, Inc.","filed_at":"2023-12-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.622120+00:00","generated_at":"2026-06-07T07:29:06.789908+00:00","sec_items":["8.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Graphite Bio clears HSR waiting period for merger with Lenz Therapeutics on Dec. 21","bullets":["HSR waiting period under Hart-Scott-Rodino Act expired at 11:59 p.m. ET on December 21, 2023.","Merger with Lenz Therapeutics, previously announced Nov. 14, 2023, remains subject to stockholder approval and other conditions.","Closing will result in Lenz becoming a wholly owned subsidiary of Graphite; combined company intends to list on Nasdaq."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-303051","json":"https://secwatch.observer/filing/0001193125-23-303051.json","markdown":"https://secwatch.observer/filing/0001193125-23-303051.md","text":"https://secwatch.observer/filing/0001193125-23-303051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815776/000119312523303051/0001193125-23-303051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815776/000119312523303051/d541575d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T07:29:06.789908+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}